Mainstream - onset.to

January 3, 2027

UK petition calls for a legal review of psilocybin access and policy, asking Parliament to consider reform for medical use, research, and reduced criminal penalties

petition.parliament.uk · Jan 3, 2027

Psilocybin Mainstream Policy Research

September 26, 2026

Kapitalismus-Crash, Cash und Psychedelika: Investor Christian Angermayer über Exit, Gehirnchips und Bitcoin

welt.de · Sep 26, 2026 · Holger Zschäpitz, Nando Sommerfeldt, WELT

Podcast Business Industry Mainstream DE

September 12, 2026

VA Secretary Doug Collins discusses fast-tracking psychedelic drug use to help veterans struggling with PTSD

foxnews.com · Sep 12, 2026

Video Clinical Mainstream Policy

September 11, 2026

The haunting of Shawn Ryan and the possible breakdown of ibogaine's alliance with the Christian right

ecstaticintegration.org · Sep 11, 2026 · Jules Evans

5-MeO-DMT Ibogaine Article Culture +2

September 8, 2026

HHS names four senior FDA leaders to advance technology, artificial intelligence, drug regulation, biologics oversight, and tobacco policy

stkt.co · Sep 8, 2026

Article Mainstream Policy Technology

September 1, 2026

Compass Pathways aims to bring the first FDA-approved psilocybin treatment to market as psychedelics approach medical mainstream

fiercepharma.com · Sep 1, 2026 · Darcy Lewis

Psilocybin Article Clinical Industry Mainstream

August 20, 2026

Radial acquires Mindful Health Solutions to expand into brain medicine as consolidation and investor interest accelerate across behavioral health and psychedelics

bhbusiness.com · Aug 20, 2026 · Chris Larson

Article Business Industry Mainstream

Australien erlaubt ab Juli 2023 den medizinischen Einsatz von Psilocybin und MDMA durch speziell zugelassene Psychiater bei therapieresistenten Störungen

psychedelia-stiftung.de · Aug 20, 2026 · Psychedelia Stiftung

Psilocybin MDMA Article Mainstream +2 DE

August 18, 2026

COMPASS Pathways reframes PTSD treatment after Lykos' MDMA setback, highlighting resilience-oriented care and the emerging role of psilocybin-assisted therapy

behavioralwire.com · Aug 18, 2026 · Behavioral Wire Staff

Psilocybin MDMA Article Industry +2

August 10, 2026

Psychedelic policy developments on August 9, 2026 span regulation, access, and legal change across jurisdictions as lawmakers and agencies reshape the field

psychedelicstoday.com · Aug 10, 2026 · Psychedelics Today

Industry Mainstream Policy

August 3, 2026

Psychedelic policy developments on August 3, 2026 track legal, regulatory, and institutional shifts affecting access, oversight, and public debate

psychedelicstoday.com · Aug 3, 2026 · Psychedelics Today

Industry Mainstream Policy

Neue Regelung zu Cannabisbluten in der GKV - Krankenkassen ubernehmen die Kosten nicht mehr und setzen auf standardisierte Extrakte

psychedelia-stiftung.de · Aug 3, 2026

Cannabis Article Mainstream Policy Safety DE

July 31, 2026

The LSD renaissance gains momentum as 8 recent studies challenge long-held myths about acid, covering safety, mental health, cognition, alcohol use, and subjective effects

thesporereport.com · Jul 31, 2026 · admin

LSD Article Mainstream Research Safety

5-MeO-DMT, known as the God Molecule, is drawing mainstream attention as a powerful psychedelic with intense effects, limited research, and significant safety risks

bloomberg.com · Jul 31, 2026

5-MeO-DMT Article Mainstream Research Safety

July 30, 2026

Psychedelic policy developments in late July 2026 track legislative, regulatory, and legal shifts affecting access, research, decriminalization, and state programs

psychedelicstoday.com · Jul 30, 2026 · Psychedelics Today

Mainstream Policy Research

July 27, 2026

Psilocybin may protect skin cells from stress and aging by reducing oxidative damage, preserving telomeres, and extending cellular lifespan in new lab research

psypost.org · Jul 27, 2026 · Eric W. Dolan

Psilocybin Article Mainstream Research

July 24, 2026

Eli Lilly's acquisition of a psychedelic biotech turned founder Christian Angermayer's stake into a $360 million windfall and highlights pharma interest in mental health drug development

forbes.com · Jul 24, 2026 · Will Yakowicz

Article Business Industry Mainstream

July 22, 2026

Big Pharma just made its biggest bet yet on psychedelics as major drugmakers and investors move deeper into ketamine, psilocybin, and next-generation mental health treatments

thesporereport.com · Jul 22, 2026 · admin

Psilocybin Ketamine Article Business +2

July 20, 2026

"Journeys" follows psilocybin therapy through personal healing stories and clinical context, highlighting preparation, guided sessions, and integration in mental health care

psychedelicstoday.com · Jul 20, 2026 · Psychedelics Today

Psilocybin Clinical Mainstream Therapy

Psychedelic policy developments on July 20, 2026 center on legal reform, regulatory shifts, and the expanding public role of psychedelics

psychedelicstoday.com · Jul 20, 2026 · Psychedelics Today

Mainstream Policy Society

July 19, 2026

Psychedelic drugs move toward mainstream mental health care as researchers, startups, and regulators test psilocybin, MDMA, and ketamine treatments

cnbc.com · Jul 19, 2026 · Bob Woods

Psilocybin MDMA Mainstream Research +2

July 16, 2026

Eli Lilly acquires Atai Beckley to expand psychedelic drug development, signaling deeper pharmaceutical investment in next-generation mental health treatments

thenew.money · Jul 16, 2026

Article Business Industry Mainstream

Eli Lilly acquires 5-MeO-DMT developer ATAI Beckley for up to $3.8 billion, signaling major pharmaceutical entry into psychedelic drug development

psychedelicalpha.com · Jul 16, 2026

5-MeO-DMT Article Business Industry Mainstream

Lilly to acquire atai Beckley for $2.8 billion upfront, expanding its neuroscience pipeline with a late-stage NMDA receptor candidate and access to psychedelic-related programs

investing.com · Jul 16, 2026

Business Industry Mainstream

Eli Lilly agrees to buy psychedelic drugmaker atai Beckley for $2.8 billion, signaling rising pharmaceutical interest in mental health treatments based on psychedelics

cnbc.com · Jul 16, 2026 · Angelica Peebles

Article Business Industry Mainstream